OptiNose, Inc. (NASDAQ:OPTN – Get Free Report) CEO Ramy A. Mahmoud sold 111,426 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $127,025.64. Following the completion of the sale, the chief executive officer now owns 1,206,978 shares in the company, valued at $1,375,954.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
OptiNose Stock Performance
OPTN stock traded down $0.02 during midday trading on Thursday, reaching $1.08. 669,865 shares of the company traded hands, compared to its average volume of 882,190. OptiNose, Inc. has a 52-week low of $0.80 and a 52-week high of $2.10. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.28. The firm has a market capitalization of $122.08 million, a price-to-earnings ratio of -4.04 and a beta of -0.12.
OptiNose (NASDAQ:OPTN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $14.88 million during the quarter, compared to analyst estimates of $13.95 million. Research analysts anticipate that OptiNose, Inc. will post -0.26 earnings per share for the current year.
Institutional Investors Weigh In On OptiNose
Analysts Set New Price Targets
OPTN has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of OptiNose in a research report on Wednesday, May 15th. Lake Street Capital decreased their target price on OptiNose from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th.
View Our Latest Research Report on OptiNose
About OptiNose
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Read More
- Five stocks we like better than OptiNose
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- High Flyers: 3 Natural Gas Stocks for March 2022
- Parabolic Rise of This Stock Shows No Signs of Slowing
- Overbought Stocks Explained: Should You Trade Them?
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.